An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia.

BUENDIA, J.; VALLEJOS C; PICHON RIVIERE, A.

BIOMéDICA

INST NACIONAL SALUD

Lugar: Bogotá; Año: 2013

0120-4157

AbstractOBJECTIVE:Trastuzumab (Herceptin), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing countries. This study assesses the cost-effectiveness of adjuvant trastuzumab treatment in Colombia.METHODS:A Markov health-state transition model was built to estimate clinical and economic outcomes in HER2-positive breast cancer with or without 12 months trastuzumab adjuvant chemotherapy over a lifetime perspective with annual transition cycles. The model incorporated five health states (diseasefree, local recurrence, distant recurrence, cardiac failure, and death). Baseline event rates and 3-year hazard ratio (HR=0.51, IC 95% 0.44-0.59; p